











doi:10.101Haploidentical In Utero Hematopoietic Cell
Transplantation Improves Phenotype and Can Induce
Tolerance for Postnatal Same-Donor Transplants in the
Canine Leukocyte Adhesion Deficiency Model
William H. Peranteau,1 Todd E. Heaton,1 Yu-Chen Gu,2 Susan W. Volk,1 Thomas R. Bauer,2
Keith Alcorn,1 Laura M. Tuschong,2 Mark P. Johnson,1 Dennis D. Hickstein,2 Alan W. Flake1In the murine model, in utero hematopoietic cell transplantation (IUHCT) has been shown to achieve low
levels of allogeneic chimerism and associated donor-specific tolerance permitting minimal conditioning post-
natal hematopoietic stem cell transplantation (HSCT). In this pilot study, we investigated IUHCT in the ca-
nine leukocyte adhesion deficiency (CLAD) model. Haploidentical IUHCTresulted in stable low-level donor
cell chimerism in all dogs that could be analyzed by sensitive detection methodology (4 of 10) through 18
months of follow-up. In the 2 CLAD recipients, low-level chimerism resulted in amelioration and complete
reversal of the CLAD phenotype, respectively. Six recipients of IUHCT (5 carriers and 1 CLAD) subse-
quently received postnatal HSCT from the same haploidentical prenatal donor after minimal conditioning
with busulfan 10 mg/kg. Chimerism in 2 of 5 CLAD carriers that underwent HSCT increased from\ 1%
pre-HSCT to sustained levels of 35% to 45%. Control animals undergoing postnatal haploidentical HSCT
without IUHCT had no detectable donor chimerism. These results demonstrate that haploidentical IUHCT
in the CLAD model can result in low-level donor chimerism that can prevent the lethal phenotype in CLAD
dogs, and can result in donor-specific tolerance that can facilitate postnatal minimal conditioning HSCT.
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transplantationINTRODUCTION
In utero hematopoietic cell transplantation
(IUHCT) is a nonmyeloablative approach that can re-
sult in low-level mixed hematopoietic chimerism with
associated donor-specific tolerance [1-5]. We have
previously shown in the murine model that donor-spe-
cific tolerance (DST) created by IUHCT can facilitate
postnatal enhancement of donor chimerism using
various minimal conditioning regimens [2,5,6]. This
represents a potential clinical strategy for the treat-
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ia, Philadelphia, Pennsylvania; and 2Experimental Trans-
tion and Immunology, Center for Cancer Research,
nal Cancer Institute, Bethesda, Maryland.
isclosure: See Acknowledgments on page 303.
dence and reprint requests: Alan W. Flake, MD, Depart-
of Surgery, Children’s Hospital of Philadelphia, Abram-
esearch Building, Room 1116B, 3615 Civic Center Blvd,
elphia, PA 19104-4318 (e-mail: flake@email.chop.edu).
eptember 8, 2008; accepted November 25, 2008
/09/153-0001$36.00/0
6/j.bbmt.2008.11.034and cured by postnatal hematopoietic stem cell trans-
plantation (HSCT). In this study, we hypothesized
that a canine model of IUHCT can be developed
that will be useful in the preclinical translation of strat-
egies developed in the murine model.
The canine model has been used extensively in the
preclinical testing of postnatal HSCT regimens and
has been a reliable predictor of clinical results [7,8];
for instance, many strategies for preventing and treat-
ing graft-versus-host disease (GVHD) were first eval-
uated in the canine model before being used in
humans [7-13]. The canine model also offers biologi-
cal and practical advantages specific to the evaluation
of IUHCT. The ontogeny of the canine immune sys-
tem appears to be relatively similar to that of humans
[14], and, from a technical perspective, the canine
pregnancy allows ultrasound-guided injection of
pups before immune maturation [15-17]. Finally, the
canine model offers the advantage of the availability
of disease models that are analogous to human disor-
ders [18-22]. One such disease model that we used in
this study is canine leukocyte adhesion deficiency
(CLAD), an autosomal recessive genetic immunodefi-
ciency disease that is the canine equivalent of human293
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and CLAD result from mutations in the leukocyte
integrin CD18 that ablate the ability of leukocytes to
adhere to the vessel wall and migrate to sites of infec-
tion [23-25]. As a result, children and dogs with LAD
suffer recurrent, life-threatening bacterial infections
[26]. In the absence of successful HSCT, CLAD
dogs have 100% mortality by age 6 months [27]. Re-
cent studies have demonstrated that even low levels
of donor cell engraftment after minimal-conditioning
matched-littermate HSCT can reverse the lethal
disease phenotype in CLAD [24,27-29].
Here we report our initial experience with IUHCT
in the CLAD model. We conclude that IUHCT can
result in stable low-level donor cell engraftment with-
out evidence of GVHD in both CLAD and CLAD-
carrier dogs. Furthermore, IUHCT can induce DST
in the canine model, with the subsequent ability to en-
hance donor chimerism in engrafted animals through
postnatal minimal conditioning HSCT from the
same donor.MATERIALS AND METHODS
Animals
Dogs were housed in the National Institutes of
Health (NIH) facilities in Bethesda and Poolesville,
Maryland, in accordance with NIH guidelines and in
the Laboratory Animal Facility of the Abramson
Research Center at The Children’s Hospital of Phila-
delphia. These facilities are approved by the American
Association for Accreditation of Laboratory Animal
Care. The experimental protocols were approved by
the Institutional Animal Care and Use Committee at
The Children’s Hospital of Philadelphia and followed
guidelines set forth in the NIH’s Guide for the Care and
Use of Laboratory Animals.
Breeding
In all cases, male or female CLAD carrier animals
were bred to reproductively intact CLAD animals that
had previously received minimal conditioning HSCT
from a DLA-matched littermate donor as described
previously [30].
Bone Marrow (BM) Harvest and CD341 Cell
Enrichment
Before IUHCTorHSCT, BMwas harvested from
parental CLAD-carrier donors and CD34-enriched as
described previously [24,28]. Because the BM was
harvested from the CLAD-carrier parent (either the
mother or the father) for both in utero and postnatal
transplantations, the donor cells expressed the
CD18/CD11 cell surface antigen. In all cases, the
donor for postnatal HSCT in previous IUHCT recip-ients was the same as the initial donor for the in utero
transplantation.
CD341 cell enrichment was performed using the
anti-canine CD34 antibody 1H6 (Fred Hutchinson
Cancer Research Center, Seattle, WA), anti-mouse
IgG1 microbeads, and the AutoMACS sorting system
(Miltenyi Biotec, Auburn, CA) [31].
CD26 Inhibition
The 3–amino acid peptide Diprotin A (Peptides
International, Louisville, KY) was used to inhibit
CD26 activity on donor cells before IUHCT, postnatal
HSCT, or in vitro migration assays. CD341-enriched
cells resuspended in ACD-A solution (Citra Anticoag-
ulants Inc. Braintree, MA) were incubated with 5 mM
Diprotin A at room temperature for 15 minutes. After
incubation, the cells were washed once (centrifugation
at 400 g for 20minutes) inACD-A solution.The cells
were recounted and either used for an in vitro migra-
tion assay or combinedwith theCD342 cell population
before transplantation, as described in the following.
IUHCT
Before undergoing IUHCT, all pregnant dogs
were examined by transabdominal ultrasonography
(Acuson Sequoia Ultrasound; Siemens, Malvern, PA)
to confirm pregnancy and determine the number of
fetuses. After BM harvest and cellular processing as de-
scribed earlier, the CD341-enriched cell and CD342
cell populations were assessed for CD3 composition
by flow cytometry. A portion of the CD342 cell popu-
lation was then added back to the entire CD341 pop-
ulation such that 1.4% to 2.4% of the final donor cell
inoculum was CD31 cells. Before injection, the final
donor inoculum was resuspended in normal saline
with 1% heat-inactivated autologous donor serum.
Gestational age was determined by retrograde cal-
culation assuming birth on gestational day 63. In brief,
after induction of general anesthesia and sterile ab-
dominal preparation, transabdominal ultrasonography
using a 7-mHz echocardiography probe was used to
identify the fetuses and their peritoneal cavities. A
22-gauge, 3.5-inch amniocentesis needle (BD, Frank-
lin Lakes, NJ) was used to inject the donor cells into
the fetal peritoneum in a total volume of 200 mL.
The amniocentesis needle was withdrawn out of the
fetal peritoneum and then used to inject 10 mg of van-
comycin in 200 mL of normal saline into the uterine
cavity. Ultrasonography was repeated after all fetuses
had been injected, to confirm postprocedure fetal
viability.
Postnatal HSCT
Six recipients of IUHCT subsequently underwent
haploidentical postnatal HSCT with minor modifica-
tions from a minimal conditioning regimen described
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The parent used as the prenatal donor also served as
the postnatal donor.Control dogs underwent postnatal
haploidentical parental BM transplantation (BMT) us-
ing the same conditioning regimen without IUHCT.
Theminimal conditioning regimen consisted of busul-
fan (Bu; Busulfex; ESP Pharma, Edison, NJ) 10 mg/kg
given over 2 hours on day22. On the day before trans-
plantation (day21), BMwas harvested from the paren-
tal donor and processed as described earlier. After
isolation of the CD341-enriched and CD342 cell pop-
ulations, the CD342 cell population was combined
with the entire CD341 cell population such that the fi-
nal donor cell inoculum contained no more than 5.5
106 CD31 cells per kilogram of recipient weight. Be-
fore the 2 cell populations were recombined, the
CD341-enriched cell population was subjected to
CD26 inhibition as described earlier. To reduce the
risk of GVHD, recipients were given a shortened
course of immunosuppression posttransplantation
consisting of cyclosporine A (CsA; Sandimmune; No-
vartis, East Hanover, NJ) 15 mg/kg twice daily from
the night of day 0 to day 35, 7.5 mg/kg twice daily
from day 36 to day 52, and 5 mg/kg twice daily from
day 53 to day 57, along with mycophenolate mofetil
(MMF; Cellcept; Roche, Nutley, NJ) 10 mg/kg twice
daily from the night of day 0 to day 28.
Flow Cytometry
The percentage and number of cells in the BMhar-
vest expressing the CD34 and CD3 antigens were de-
termined by flow cytometry before IUHCT or
postnatal BMT. In 2 separate reactions, 1  106 BM
cells were stained with a phycoerythrin (PE)-conju-
gated anti-canine CD34 antibody (1H6; Pharmingen,
San Diego, CA) and a PE-conjugated anti-canine
CD3 antibody (Serotec, Raleigh, NC) and then ana-
lyzed by flow cytometry on a FACSCalibur (BD).
Peripheral blood (PB) samples from the IUHCT
recipients were analyzed by flow cytometry at age 1
month for expression of the CD18 antigen to identify
them as either CLAD-carrier (CD181) or CLAD-
affected dogs. Cells were stained with anti-CD18
monoclonal antibodies (mAbs) as described previously
[32]. The CLAD dogs underwent monthly CD18 PB
analysis up to age 18 months.
DNAChimerismAnalysis Using SRYPolymerase
Chain Reaction (PCR) and SRY TaqMan
Real-Time
Donor cell engraftment was assessed for the male-
specific SRY gene in female recipients of male donors
by PCR as described previously [33]. In brief, DNA
was extracted from the PB and amplified with SRY-
specific primers (forward: 25´-CTCGCGATCAAAG
GCGCAAGAT-3´; reverse: 5´-TTCGGCTTCTGTAAGCATTTTC-3´) on an Eppendorf Mastercycler
(Eppendorf, Hamburg, Germany) by denaturing for
94C for 90 seconds, followed by 35 cycles of 94C
for 15 seconds, 58C for 15 seconds, 72C for 20 sec-
onds, and then a final extension of 72C for 10 min-
utes. Products were run on a 1.5% agarose gel and
visualized by ethidium bromide staining.
Chimerism in female recipients of male donor BM
was quantified using a TaqMan SRY quantitative PCR
(Q-PCR) protocol on a real-time PCR instrument
(model 7500; Applied Biosystems, Foster City, CA),
as described previously [34]. In brief, triplicate reac-
tions were prepared using 2 real-time PCR master
mix (forward primer: CCCCATGAACGCATT
CTTG; reverse primer: CTGATCTCTGAGTTT
TGCATTTGG; 5´ FAM conjugated probe: TCTC
GCGATCAAAGG [Applied Biosystems]). Experi-
mental samples were quantified through comparison
with a standard curve derived from mixing known
quantities of male DNA and female DNA. During
construction of the standard curve, the assay was deter-
mined to be sufficiently sensitive to detect 0.01%male
DNA in female DNA.
DNA Chimerism Analysis Using PCR for DNA
Microsatellite Repeat Markers
Chimerism in CLAD carriers that had undergone
BMT (either IUHCT or postnatal BMT) from a fe-
male donor or male recipients of a male donor could
not be assessed by flow cytometry for the CD18 anti-
gen or by PCR for the SRY gene. In these recipients,
the percentage of donor chimerism in PB leukocytes
was determined using DNA microsatellite repeat
markers that distinguished donor and recipient DNA
contributions, as described previously [29].
CLAD Clinical Phenotype Analysis
The CLAD dogs were monitored on a daily basis
for evidence of the CLAD phenotype starting at 3
weeks of life and extending until the end of the study.
Seven distinct clinical areas (temperature, comfort,
movement, appearance, behavior, interactive behavior,
and vocalization) were evaluated and ranked on a scale
of 0 to 4, with the sum of the scores representing the
clinical score.
Mixed Lymphocyte Reaction
In vitro mixed lymphocyte reactions (MLRs) were
performed to assess the reactivity of recipient PB
mononuclear cells (PBMCs) to donor PBMCs. In
brief, PB was diluted in clinical-grade normal saline
and layered over NycoPrep 1.077A (Griener Bio-Onc,
Longwood, FL). Cells were centrifuged at 800  g
for 30 minutes at room temperature. The mononuclear
cell layer was harvested, washed twice (centrifuged @
400  g for 15 minutes @ 4C) with PBS with 0.1%
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counted. Cells to be used as stimulators were irradiated
at 20 Gy, and cells to be used as responders were
stained with carboxyfluorescein diacetate succinimidyl
ester (CFSE) (Molecular Probes, Eugene, OR) in ac-
cordance with the manufacturer’s instructions. Irradi-
ated stimulator and CFSE-labeled responder cells
were resuspended in RPMI 1640 medium with 10%
heat-inactivated fetal calf serum (FCS) and 1000 mL
of 2-mercaptoethanol at a concentration of 2  105
cells per 200 mL. Responder and stimulator cells
weremixed at a 1:1 ratio in 96-well tissue culture plates
in a total volume of 400 mL per well. Cells were incu-
bated at 37Cwith 5%CO2 and harvested 5 days and 7
days after initial mixing for analysis of responder cell
division by flow cytometry for CFSE as described
previously [35].
In Vitro Migration of BM Cells with and without
CD26 Inhibition
Chemotaxis assays were performed on 24-well
transwell plates (6.5 mm diameter, 5 mm pore size pol-
ycarbonate membrane; Costar, Cambridge, MA) to
assess the effect of CD26 inhibition on stromal cell–
derived factor (SDF) 1a–induced migration as de-
scribed previously, with minor modifications [36].
BM cells were harvested with or without CD341 cell
enrichment and either received CD26 inhibition as de-
scribed earlier or were unmanipulated. Then 5  105
inhibited or noninhibited cells were added to the upper
wells in 200 mL of Iscove’s modified Dulbecco’s me-
dium with 20% fetal bovine serum (FBS) and 1 mL
of the same medium with 0 ng/mL, 50 ng/mL, 100
ng/mL, or 200 ng/mL of recombinant human/rhesus
macaque/feline CXCL12/SDF-1a (R&D Systems,
Minneapolis, MN) was added to the bottom well.
The cells were incubated at 37C in 5% CO2 for 4
hours, after which the number and percentage of cells
that migrated to the bottom well were calculated. All
conditions were performed in triplicate.
GVHDAnalysis
Dogs were evaluated for any clinical signs of
GVHD, including anorexia, conjuctival or skin ery-
thema, diarrhea, and weight loss. At the time of blood
sampling for chimerism analysis, the bilirubin and liver
function tests of recipients of postnatal BMT were
evaluated for elevations consistent with GVHD. InTable 1. Summary of IUHCT
Mother GA, Days Donor Source CD34 Cells/kg CD3 Cells/kg Percentage
Tonic 40 Mother 4.8  108 7.8 106 1.
Dancer 50 Father 1.7  108 5.7  106 2.
Vixen 37 Father 2.2  108 5.9  106 1.
IUHCT indicates in utero hematopoietic cell transplantation. Pregnant females
calculated retrospectively assuming birth at gestational day 63. All fetuses preaddition, the bilirubin and liver function tests of all
IUHCT recipients were evaluated at age 3 months.
Finally, histological analyses of the liver, skin, and in-
testine of dogs that died during the neonatal period
were performed to assess for evidence of GVHD.
Statistical Analysis
All data (where applicable) are represented as mean
6 standard error of the mean. Statistical comparisons
between groups were done using the Student t test for
2 samples assuming unequal variances. A 2-tailed P
value # .05 was considered significant.RESULTS
IUHCT
We injected a total of 15 fetuses from 3 pregnant
dogs. Data regarding gestational age, number of fe-
tuses per female, and doses and composition of the cel-
lular graft are summarized in Table 1. The overall
perinatal mortality of 33% (5 of 15 injected fetuses
died during the perinatal period) was related to postna-
tal mortality rather than to in utero death. Four of the
5 deaths occurred within the first 2 days of life.
Although the exact causes of postnatal death were un-
clear, maternal neglect contributed to at least 1 death.
Histological analysis of the skin, intestine, and liver of
the diseased pups demonstrated no evidence of
GVHD, and no sites of infection were apparent on tis-
sue examination. Analysis of engraftment could not be
performed reliably because of the condition of the
hematopoietic tissues after death.
Chimerism in the CLAD-Carrier Dogs after
IUHCT
Eight of the 10 surviving injected fetuses were
CLAD carriers (Table 2), in which analysis of chime-
rism by CD18 expression after IUHCT could not be
performed. Instead, chimerism analysis was performed
by PCR for DNA microsatellite repeat markers in all
recipients as well as by PCR and quantitative TaqMan
PCR for the male-specific SRY gene in female recipi-
ents (Ella and Bonnie) of male donors. Evaluation of
all CLAD-carrier recipients by PCR analysis for
DNA microsatellite repeat markers, which has a sen-
sitivity of approximately 5%, did not demonstrate de-




were injected at the indicated gestational age (GA). GA at injection was
sent in the mothers were injected.
Table 2. Geneology of Surviving Pups
Mother Pup Sex Genotype
Tonic Baku Male Carrier
Kojin Female Carrier
Benton Female Carrier





Vixen Bonnie Female Carrier
Clyde Male Carrier
CLAD indicates canine leukocyte adhesion deficiency.
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the SRY gene in female recipients of a male donor de-
tected chimerism in both Ella and Bonnie at all time
points evaluated. Quantification of the donor chime-
rism in Ella by TaqMan PCR for the SRY gene con-
firmed that donor cell engraftment had occurred,
albeit at very low levels (0.1% to 0.5%). Importantly,
this assay detected no SRY-positive cells in female
pups that did not undergo IUHCT (n 5 4) or female
recipients of female donors after IUHCT (n 5 2), ar-
guing against any transplacental acquisition of male
microchimerism.
Chimerism in the CLAD Dogs after IUHCT
Two of the dogs from Dancer’s litter, Duke and
Billie, were CLAD affected; in these dogs, analysis
for PB chimerism could be performed by flow cyto-
metric analysis of CD18 expression. This analysis
demonstrated that both dogs had stable low levels of
donor cell engraftment at all time points analyzed after
IUHCT (Figure 1). Billie’s analysis extends up to age
18months of life, the latest time point assessed. Duke’s
analysis stops at age 7 months, when he underwent
postnatal same-donor transplantation. We elected to
perform transplantation in Duke once a baseline effi-
cacy of IUHCT had been established, because of his
low-grade infections and inability to wean from antibi-
otics. Multilineage donor engraftment was demon-
strated in both dogs in the T cell, B cell, neutrophil,
andmonocyte lineages at all of the time points assessed
(Figure 1B and C). Finally, because Billie was a female
recipient of a male donor, donor cell engraftment was
confirmed by PCR for the SRY gene. As shown in
Figure 2, Billie’s engraftment level determined by
TaqMan SRY PCR corresponded closely to those
detected by flow cytometry for CD18 expression.
Improvement in the CLAD Phenotype after
IUHCT
In contrast to historical CLAD controls, which
demonstrate 100% mortality by 6 months of life, the
2 chimeric CLAD dogs (Billie and Duke) in the
current study were alive and healthy throughout the
unmanipulated follow-up period [28] (Figure 3).Duke displayed a mildly affected CLAD phenotype,
but never required intensive care. At age 7 months,
Duke underwent a postnatal transplantation, as dis-
cussed below, during which time he experienced no
CLAD-phenotypic events. He was subsequently eu-
thanized because of graft rejection and worsening
CLAD phenotype. In contrast to Duke, Billie has
never displayed any CLAD phenotypic events and
has remained completely healthy throughout the study
period (18 months). In addition, in contrast to histor-
ical CLAD-affected dogs, which demonstrate a leuko-
cytosis with white blood cell (WBC) counts . 50,000
cells /mL, Billie consistently demonstrated normal to
slightly elevated WBC counts, whereas Duke’s WBC
counts before boosting were moderately elevated, but
still\ 50,000 cells/mL (Figure 3B).
GVHD after IUHCT
None of the dogs demonstrated any clinical signs
of GVHD. All dogs exhibited appropriate weight
gain (data not shown) and liver enzyme or bilirubin
levels. These data argue against the presence of
GVHD in any of the IUHCT recipients.
MLR
In vitro MLRs were performed to assess the reac-
tivity of PBMCs from Tonic’s and Dancer’s litters to
prenatal donor and unrelated third-party stimulator
cells. The reactivity of responder cells to prenatal do-
nor and third-party stimulator cells was standardized
to the reactivity of responder cells to autologous stim-
ulator cells. As shown in Figure 4, Baku demonstrated
no increased reactivity to prenatal donor cells over re-
sponse to self. Kojin, Billie, Louie, Miles, and Benten
demonstrated decreased reactivity to the prenatal do-
nors compared with unrelated third-party stimulators,
but the differences did not reach statistical signifi-
cance. Ella and Duke, however, demonstrated equal
or greater reactivity to the prenatal donor compared
with third-party unrelated stimulator cell populations.
Postnatal Same-Donor Haploidentical HSCT in
Recipients of IUHCT
Six recipients of IUHCT (5 CLAD carriers and 1
CLAD affected) underwent postnatal HSCT using
the same prenatal donor. Recipients were conditioned
with anonmyeloablative dose ofBu and received a short
course of posttransplantation immunosuppression
with CsA and MMF for GVHD prophylaxis. The age
at transplantation, total cell dose, and CD341 and
CD31 cell components of the donor cell inoculums
are summarized in Table 3. All of the IUHCT recipi-
ents exhibited a dramatic increase in chimerism levels
that peaked between 3 and 10 weeks posttransplanta-
tion. Two CLAD carriers, Baku and Louie, demon-
strated a dramatic and substantial increase in donor
Figure 1. Chimerism in the CLADmodel after IUHCT. (A) PB was analyzed monthly by flow cytometry for the CD18 antigen in the CLAD dogs Duke
and Billie. Duke’s chimerism analysis stopped at 7 months, because he underwent postnatal transplantation at that time. For mulitlineage analysis, PB
samples from Billie (B) and Duke (C) were analyzed at the indicated time points by flow cytometry for donor neutrophils, monocytes, B cells, and T cells.
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levels of 35% to 45% (Figure 5). However, the remain-
ing 3 CLAD carrier dogs lost a detectable level (sensi-
tivity 5 5%) of donor cell engraftment by 14 weeks
posttransplantation. Duke, the only CLAD dog that
underwent postnatal transplantation, demonstrated
a dramatic increase in chimerism levels that peaked
at 6 weeks posttransplantation; however, his donor
cell engraftment dropped to pre postnatal boosting
levels at 8 weeks posttransplantation. Terry and Cash-
mere did not undergo IUHCT, but only received
postnatal maternal BMT, and, thus, they served as
postnatal transplantation controls. These 2 dogs never
demonstrated any detectable level of donor cell chime-
rism.Clinical Phenotype and GVHD After Postnatal
Transplantation
No dog demonstrated clinical evidence of GVHD.
With the exception of a transient peritransplantation
weight loss attributed to the decreased appetite associ-
ated with the conditioning regimen, all dogs demon-
strated appropriate weight gain posttransplantation
(data not shown).Dukedemonstrated noCLADpheno-
typic episodes in the posttransplantation period, during
which timehis chimerism levels remainedelevated.After
the lossof chimerism,Dukeagain revertedback toamild
CLAD phenotype, experiencing clinical events and leu-
kocytosis at the same frequency and intensity that he
experienced before the postnatal transplantation until
he was euthanized at age 15 months.
Figure 2. Engraftment after IUHCT in a female CLAD recipient: correlation of flow cytometry and TaqMan PCR. (A) In Billie, a female CLAD recipient
of male donor BM, donor engraftment was confirmed by PCR for the SRY gene. (B) Chimerismwas quantified by SRY TaqMan PCR, and levels were found
to be similar to those determined by flow cytometry for the CD18 antigen.
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CD26 inhibition has been demonstrated to increase
the efficiency and levels of engraftment after IUHCT
in a mouse model [37]. In the current study, we empir-
ically included CD26 inhibition of the CD341 cell
component of the donor cell inoculums before IUHCT
and postnatal BMT. To explore whether CD26 inhibi-
tion has the potential to affect canine CD341 cell mi-
gration, we performed an in vitro chemotaxis assay to
assess the affect of CD26 inhibition of whole BM and
CD341-enriched BM on SDF-1a induced migration.
As demonstrated in Figure 6, CD26 inhibition of
both cell populations resulted in an increased percent-
age of cell migration to an SDF-1a source. The
difference in migration between CD26-inhibited
and -noninhibited cells was most prominent when
CD341-enriched BM cells were analyzed.DISCUSSION
IUHCToffers the potential to treat many hemato-
logic genetic disorders without the need for the
myeloablative conditioning regimens currently used
for haploidentical and mismatched postnatal HSCT
protocols. Early success in the sheep model suggested
that significant levels of allogeneic engraftment could
be achieved relatively easily by IUHCT. However,
with the exception of immunodeficiency disorders
[38-40], this proved not to be the case in humans
and other animal species, in which early clinical andexperimental studies resulted in limited or no detect-
able engraftment. Subsequent experimental studies in
mice have confirmed that there are both competitive
and immunologic barriers to engraftment after
IUHCT [37,41,42]. But these barriers can be over-
come (at least in a percentage of animals), to achieve
low levels of mixed hematopoietic chimerism across
full major histocompatibility complex barriers, with
associated DST. Apparently, a threshold of chimerism
of around 1% is required for consistent association of
DST in the murine model [6]. Chimerism levels below
this threshold result in inconsistent tolerance, with
only a fraction of animals accepting skin grafts or dem-
onstrating enhanced chimerism after postnatal same-
donor transplantation [3-6]. In mice, animals that are
tolerant after IUHCT can undergo transplantation af-
ter birth using various minimal conditioning strategies
with enhancement of donor chimerism to levels that
would be therapeutic for most target disorders
[2,5,6]. With this potential clinical strategy in mind,
we wished to develop a preclinical model in which
techniques developed in themurinemodel could be as-
sessed for their applicability to human disease.
In the present study, we were able to perform
IUHCT in the CLAD model using clinically applica-
ble methodology with perinatal mortality similar to
that seen after the natural breeding of dogs [43].
IUHCT using haploidentical donors resulted in
low levels of mixed hematopoietic chimerism that
remained stable for more than 18 months. The low
levels of chimerism achieved in both the CLAD and
Figure 3. Clinical phenotype of chimeric CLAD dogs after IUHCT. (A) The CLAD dogs were monitored and scored using the sum of 7 clinical param-
eters of temperature, comfort, movement, appearance, behavior, interactive behavior, and vocalization. A score ranging from 0 for normal to 4 for max-
imal abnormality in each category was assigned at each data point. Data are shown for up to 7 months of life for Duke, at which point he underwent
postnatal BMT. Billie continued to experience no CLAD clinical events up to the last time point assessed, at 18 months of life (not represented on the
graph). (B) Billie’s and Duke’s WBC counts were assessed for leukocytosis (. 50,000 cells/mL), which is typical of CLAD-affected dogs.
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engraftment milieu in the canine fetus, which appears
to be analogous to that in humans. Remarkably, all
dogs that could be analyzed with sensitive methodol-
ogy (ie, CD18 or SrY Q-PCR) were engrafted after
IUHCT. In the animals in which lineage analysis
could be performed, donor chimerism was multiline-
age and durable, supporting the engraftment of HSC
at the time of IUHCT. Consistent with previous post-
natal studies in the CLADmodel, we demonstrate that
even the low levels of engraftment achieved after
IUHCT are adequate to phenotypically ameliorate
or correct the disease.
Perhaps the most important observation of this
study is the ability of IUHCT to induce DST in 2 of
the chimeric animals, as evidenced by the ability to en-
hance engraftment after birth using a nonmyeloabla-
tive conditioning regimen with sustained high levels
of donor chimerism thereafter. This was in distinctcontrast to what would be expected for haploidentical
transplantations using the same conditioning regimen
in the absence of induction of tolerance by IUHCT.
We used CFSE MLR to assess for the presence of
DST. The one dog that demonstrated definitively
decreased donor-specific reactivity (Baku) also was
successfully boosted, whereas the one dog that demon-
strated definitive reactivity to donor cells and also un-
derwent postnatal transplantation (Duke) rapidly lost
donor chimerism. The rest of the dogs that were as-
sessed by MLR exhibited intermediate results. Each
of these dogs demonstrated an initial rise in chimerism
levels, with subsequent loss of engraftment by 14weeks
post-HSCT. This pattern of engraftment was distinct
from the complete absence of chimerism seen in the
non-IUHCT control dogs, in which donor chimerism
could not be detected at any time after HSCT. These
data support our premise that IUHCT is associated
with DST, at least in a subset of recipients; however,
Figure 4. Recipients of IUHCTwere evaluated by in vitro MLR for reactivity against donor cells compared with reactivity against self and unrelated
third-party cells. MLR was performed with CFSE staining. (A) Increased cell division/reactivity is indicated by decreased intensity of CFSE staining
and a shift of cells from population 1 (P1) to population 3 (P3). (B) The reactivity (or percentage of cells in each population) of recipients to self cells
was standardized to 100%, as indicated by the dotted line, and the reactivity of recipients to third-party and prenatal donor cells was compared with this
standard. Thus, a bar above the dotted line indicates a larger percentage of cells in that population compared with the percentage of cells in the self-
reactive negative control assay.
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transplantation in this study, as well as limitations in
the assessment of tolerance in the canine model, we
have not absolutely proved that DST resulted from
IUHCT.
Our data in the canine model can be compared and
contrasted with results in the murine model. Although
levels of engraftment in chimeric dogs are generally
lower than what can be achieved in mice, the frequency
of engraftment appears to be at least as high (andperhaps higher) in the dog as in the mouse. Sustained
chimerism is observed in only around 30% of mice af-
ter allogeneic IUHCT, whereas in the present study,
every dog in which sensitive detection methodology
could be applied after IUHCT demonstrated sus-
tained chimerism. The canine model appears to be re-
markably similar to the murine model with respect to
the correlation of the level of chimerism with the ap-
parent association of DST. In the murine model,
only approximately 60% of animals with \ 1%










Baku 4 72  106 8  106 1  106
Duke 7 160  106 2.6  106 5.5  106
Kojin 8.5 130  106 7  106 2.6  106
Louie 10 159  106 5.5  106 1.2  106
Miles 11 126  106 3.2  106 4.2  106
Benten 11 91  106 8.6  106 4.5  106
Terry 4 170  106 2.5  106 2.3  106
Cashmere 4 170  106 2.5  106 2.3  106
BMT indicates bone marrow transplantation. Six dogs underwent post-
natal BMTusing the same donor that had been used for their prenatal
BMT. Two dogs (Terry and Cashmere) did not undergo prenatal BMT
and only underwent postnatal BMT in which their mother served as
the donor.
302 Biol Blood Marrow Transplant 15:293-305, 2009W. H. Peranteau et al.chimerism will demonstrate enhanced chimerism with
a Bu-conditioned same-donor HSCT, whereas 100%
of animals with . 1% chimerism can be boosted [6].
In this study, where levels of chimerism appear to be
#1%, 2 of 6 total dogs and 2 of 5 CLAD carriers that
underwent postnatal same donor transplantation ex-
hibited a sustained increase in the level of donor chime-
rism. Thus, we would anticipate, based on our murine
data, that the achievement of levels of donor chimerism
even slightly higher than those in the current study
should result in the consistent association of tolerance
and allow all recipients of IUHCT to be boosted to po-
tentially therapeutic levels of chimerism after birth.
The primary clinical risk of IUHCT is expected to
be GVHD. Although the number of dogs that under-
went transplantation in this initial experience was too
small to allow us tomake a confident statement regard-
ing the risks of IUHCT in a large-animal system, we
found it encouraging that despite the intentional addi-
tion of significant numbers of T cells, we observed
no GVHD. Our protocol for T cell reconstitution in
this study was adapted from studies in the pig model
of IUHCT, in which multilineage chimerism with
DST was achieved after BM was T cell–depleted and
unprocessed whole BM was added back to achieve
a T cell concentration of 1.5% [44,45]. This was inFigure 5. Donor cell engraftment after postnatal ‘‘boosting’’ BMT. Six dogs un
Two dogs (Terry and Cashmere) did not undergo prenatal BMTand only unde
Cashmere demonstrated no donor cell engraftment at any time point analyzecontrast to the strictly lymphoid chimerism that re-
sulted from the add-back of isolated CD31 cells at
the same CD31 dose, suggesting that other popula-
tions in BM besides T cells may be important in facil-
itatingHSCengraftment after IUHCT.Earlier studies
in the sheep and primate models of IUHCT have used
similar T cell doses to support engraftment [46,47]. In
the current study, T cell doses as high as 7.8  106
CD31 cells/kg estimated fetal weight were adminis-
tered without evidence of GVHD; however, the upper
limit of T cell dose and the safety profile of T cell dos-
ing with or without other cell populations remain to be
defined. Further studies in the caninemodel are needed
before any conclusions can be drawn regarding the
safety of various T cell doses after IUHCT.
The results of the current study compare favorably
and extend the results of Blakemore et al. [48], who
were the first to assess allogeneic IUHCT using hap-
loidentical donor cells in the normal canine model.
Similar to us, they found an overall perinatal mortality
rate of 31%. They performed analysis for donor cell
chimerism in harvested hematopoietic tissues at a sin-
gle, short-term time point in the neonatal period.
Their findings suggest the presence of low levels
(0.01% to\ 2%) of donor cell chimerism in some of
the tissues of some recipients. But they were unable
to demonstrate any evidence of DST after IUHCT
by in vitro MLR. Interestingly, there did not appear
to be a relationship between T cell dose and level of
chimerism, and no GVHD was observed at even
high T cell doses. Beyond the observations that low-
level chimerism can be achieved without GVHD,
direct comparisons between our data and that of Blake-
more et al. [48] are difficult, because of methodological
differences in donor cell preparations and donor cell
detection, and particularly the major difference in
duration of follow-up.
In the current study, we used a protocol of Bu con-
ditioningwith a short course of posttransplantation im-
munosuppression for GVHD prophylaxis. This
regimen has been shown to result in successfulderwent postnatal BMTusing the same donor as for their prenatal BMT.
rwent postnatal BMT, with their mother serving as the donor. Terry and
d and are thus not represented on the graph.
Figure 6. Chemotaxis assay to SDF-1a gradient after CD26 inhibition.
Canine BM-derived enriched CD341 cells (A) and whole BM (B) were
subjected to CD26 inhibition by incubation with Diprotin A or were un-
manipulated (control) and assessed for SDF-1a–mediated chemotaxis
after 4 hours of incubation at 37C in Transwell chemotaxis chambers.
As indicated, cells were incubated with Diprotin A at either 37C or
room temperature for 15 minutes before being placed in the chemotaxis
chambers. Migration at all SDF-1a concentrations was assessed in trip-
licate.
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however, as observed in our control animals and in pre-
vious postnatal experience (D. Hickstein, personal
communication), it does not allow for successful paren-
tal haploidentical engraftment in recipients that did not
undergo IUHCT. In this study, 2 of the IUHCTrecip-
ients demonstrated successful long-term enhanced en-
graftment after same-donor postnatal haploidentical
HSCT. Engraftment levels in these recipients re-
mained stable at 35% to 45% donor cell chimerism
up to the last time point of analysis. The remaining 4
IUHCT recipients all experienced an initial rise in chi-
merism, but subsequently lost measurable engraftment
by 14 weeks posttransplantation. Although the initial
rise in engraftment level was encouraging, and was dis-
tinct from the engraftment pattern seen in the 2 control
dogs that did not undergo IUHCT, we believe that the
loss of chimerism seen in these recipients reflects an im-
mune rejection. Because of technical limitations of
quantifying chimerism in the canine model, we were
unable to determine the original presence or levels of
engraftment in 4 of the 6 IUHCT recipients that un-
derwent postnatal transplantation. The sensitivity of
the assay used to detect chimerism is 5%; thus we
know that engraftment, if present, occurred at chime-
rism levels\ 5% in these dogs. In addition, based on
IUHCT engraftment levels seen in Billie, Ella, Duke,
and Bonnie, we can reasonably assume that chimerism
levels were\1%. Thus, it is not surprising that all an-
imals did not demonstrate evidence of tolerance.Finally, we believe that the temporary enhancement
of chimerism in those dogs in which engraftment after
IUHCT could not be determined supports the pres-
ence of chimerism, because our experience with
IUHCT has demonstrated that no tolerance occurs
without concomitant donor cell chimerism.
Although this study is a valuable first step toward
optimization of IUHCT for clinical application,
much more work remains to be done. Basic questions,
such as the optimal timing of transplantation and cor-
relation with specific stages of immune and hemato-
poietic development, require further investigation.
Althoughmany questions remain, our findings provide
encouraging evidence that IUHCT can result in
successful engraftment and induction of DST in a pre-
clinical large-animal model. Although we have demon-
strated that the low levels of engraftment achieved by
IUHCT can reverse the lethal phenotype of CLAD,
we consider the most exciting aspect of our study to
be the apparent finding that IUHCT can induce
DST in some circumstances, and that this tolerance
can provide a platform for postnatal minimal condi-
tioning HSCT with enhancement of donor cell en-
graftment to clinically relevant levels. We believe
that if further enhancement of engraftment can be
achieved in this model with consistent tolerance induc-
tion, than appropriate clinical trials of IUHCT for the
treatment of genetic disorders that can be prenatally
diagnosed and treated by mixed hematopoietic chime-
rism, such as the hemoglobinopathies and selected
immunodeficiency disorders, could be initiated.ACKNOWLEDGMENTS
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